Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07225439 · ClinicalTrials.gov registry record · Phase 1
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
A Phase 1 study, sponsored by Paolo Caimi, MD.
- Not yet
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT07225439 is a Phase 1 study that has not yet begun recruiting, run by Paolo Caimi, MD. The registered enrollment target is 15 participants.
The verdict
NCT07225439, a Phase 1 study, has not yet begun recruiting, sponsored by Paolo Caimi, MD.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death). Participants in this study will receive lymphodepleting chemotherapy, as well as Allogeneic NK cells, Tafasitamab and Interleukin-2 (IL-2) by an intravenous (IV) infusion. Participants are expected to complete one cycle, and they may be eligible to complete a second cycle of the same regiment if they have stable disease, partial or complete remission at the end of the first cycle. Participants will be in this study for about 12 months.
Interventions
- DRUG Rituximab
- DRUG Interleukin-2
- DRUG Tafasitamab
- DRUG Allogeneic NK cells
- DRUG Fludarabine/cyclophosphamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-09 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07225439
The ClinicalTrials.gov registry entry for NCT07225439 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Paolo Caimi, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT07225439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07225439 about?
NCT07225439 is a clinical study titled "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)". This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for t...
What is the current status of trial NCT07225439?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-09. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07225439?
The interventions under investigation include: Rituximab (DRUG), Interleukin-2 (DRUG), Tafasitamab (DRUG), Allogeneic NK cells (DRUG), Fludarabine/cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT07225439?
This trial is sponsored by Paolo Caimi, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.